MNG446
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.337
- HYPOXIA+0.228
- GLYCOLYSIS+0.211
- UNFOLDED_PROTEIN_RESPONSE+0.192
- PANCREAS_BETA_CELLS+0.164
- MTORC1_SIGNALING+0.143
- E2F_TARGETS+0.124
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.117
- ANGIOGENESIS+0.102
- ANDROGEN_RESPONSE+0.070
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.381
- APICAL_JUNCTION-0.351
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.340
- INTERFERON_GAMMA_RESPONSE-0.322
- INFLAMMATORY_RESPONSE-0.266
- WNT_BETA_CATENIN_SIGNALING-0.238
- MITOTIC_SPINDLE-0.234
- TNFA_SIGNALING_VIA_NFKB-0.233
- ALLOGRAFT_REJECTION-0.226
- MYOGENESIS-0.226
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG363 | — | — | 0.754 |
| 2 | TCGA-KU-A66T-01A-11R-A30B-07 | — | — | 0.748 |
| 3 | TCGA-E9-A54X-01A-11R-A266-07 | — | B | 0.739 |
| 4 | TCGA-D8-A1XV-01A-11R-A14M-07 | — | B | 0.737 |
| 5 | MNG79 | — | — | 0.727 |
| 6 | MNG775 | — | — | 0.716 |
| 7 | 4a73aaff-d7fa-40d2-92f8-c9539055d35c | — | — | 0.706 |
| 8 | MNG640 | — | — | 0.705 |
| 9 | BS_FW5ECXXK | Supratentorial Ependymoma | — | 0.698 |
| 10 | SAMN03290890 | — | — | 0.695 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.337 | Remibrutinib | — uncovered |
| HYPOXIA | 0.228 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.211 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.192 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.164 | Cobimetinib | — uncovered |
| MTORC1_SIGNALING | 0.143 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.124 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.117 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.102 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.070 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.059 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.058 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.048 | Inavolisib | — uncovered |
| COAGULATION | 0.040 | Binimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.026 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.022 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.008 | Inavolisib | — uncovered |